Compare OSS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSS | CRBU |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.3M | 203.9M |
| IPO Year | 2017 | 2021 |
| Metric | OSS | CRBU |
|---|---|---|
| Price | $9.10 | $1.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $10.00 | ★ $10.75 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 03-18-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.85 | 3.64 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $37,027,382.00 | N/A |
| Revenue This Year | $13.57 | $1.63 |
| Revenue Next Year | $23.40 | $10.93 |
| P/E Ratio | $40.23 | ★ N/A |
| Revenue Growth | ★ 34.46 | N/A |
| 52 Week Low | $1.85 | $0.66 |
| 52 Week High | $12.75 | $3.53 |
| Indicator | OSS | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 49.21 |
| Support Level | $7.95 | $1.70 |
| Resistance Level | $10.74 | $2.07 |
| Average True Range (ATR) | 0.96 | 0.12 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 22.80 | 42.68 |
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy. The company operates in two reportable segments; OSS designs and manufactures high-performance customized computers and flash arrays, in-flight entertainment & connectivity. Bressner operates as a system integrator with standard and custom all-in-one hardware systems and components for many kinds of industrial environments. The company generates the majority of its revenue from the Bressner segment.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.